Swiss National Bank
PACB icon

Swiss National Bank’s Pacific Biosciences PACB Stock Holding History

Swiss National Bank’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-475,246
Closed -$561K – 2385
2025
Q1 		$561K Hold
475,246
– – ﹤0.01% 2322
2024
Q4 		$870K Hold
475,246
– – ﹤0.01% 2262
2024
Q3 		$808K Hold
475,246
– – ﹤0.01% 2307
2024
Q2 		$651K Hold
475,246
– – ﹤0.01% 2353
2024
Q1 		$1.78M Buy
475,246
+6,200
+1% +$36.3K ﹤0.01% 1901
2023
Q4 		$4.6M Sell
469,046
-52,800
-10% -$432K ﹤0.01% 1342
2023
Q3 		$4.36M Buy
521,846
+5,200
+1% +$59.4K ﹤0.01% 1362
2023
Q2 		$6.87M Buy
516,646
+53,000
+11% +$644K ﹤0.01% 1121
2023
Q1 		$5.37M Sell
463,646
-52,100
-10% -$518K ﹤0.01% 1224
2022
Q4 		$4.22M Buy
515,746
+10,300
+2% +$88.7K ﹤0.01% 1431
2022
Q3 		$2.93M Buy
505,446
+9,900
+2% +$56.8K ﹤0.01% 1618
2022
Q2 		$2.19M Hold
495,546
– – ﹤0.01% 1845
2022
Q1 		$4.51M Buy
495,546
+80,000
+19% +$921K ﹤0.01% 1506
2021
Q4 		$8.5M Sell
415,546
-900
-0.2% -$21.7K 0.01% 1109
2021
Q3 		$10.6M Buy
416,446
+12,100
+3% +$358K 0.01% 969
2021
Q2 		$14.1M Sell
404,346
-2,000
-0.5% -$58.2K 0.01% 845
2021
Q1 		$13.5M Buy
406,346
+32,800
+9% +$1.15M 0.01% 848
2020
Q4 		$9.69M Hold
373,546
– – 0.01% 951
2020
Q3 		$3.69M Buy
373,546
+66,100
+21% +$381K ﹤0.01% 1365
2020
Q2 		$1.06M Buy
307,446
+55,200
+22% +$188K ﹤0.01% 2066
2020
Q1 		$772K Buy
252,246
+3,400
+1% +$13.9K ﹤0.01% 1975
2019
Q4 		$1.28M Buy
248,846
+5,200
+2% +$26.4K ﹤0.01% 1997
2019
Q3 		$1.26M Buy
243,646
+4,700
+2% +$26.3K ﹤0.01% 1936
2019
Q2 		$1.45M Sell
238,946
-5,300
-2% -$37.2K ﹤0.01% 1899
2019
Q1 		$1.77M Buy
244,246
+11,800
+5% +$85.3K ﹤0.01% 1742
2018
Q4 		$1.72M Buy
232,446
+8,200
+4% +$52K ﹤0.01% 1671
2018
Q3 		$1.21M Buy
224,246
+33,000
+17% +$142K ﹤0.01% 2035
2018
Q2 		$679K Hold
191,246
– – ﹤0.01% 2355
2018
Q1 		$392K Buy
191,246
+22,600
+13% +$58.7K ﹤0.01% 2432
2017
Q4 		$445K Hold
168,646
– – ﹤0.01% 2435
2017
Q3 		$885K Hold
168,646
– – ﹤0.01% 2131
2017
Q2 		$600K Buy
168,646
+30,000
+22% +$121K ﹤0.01% 2351
2017
Q1 		$717K Hold
138,646
– – ﹤0.01% 2217
2016
Q4 		$527K Hold
138,646
– – ﹤0.01% 2370
2016
Q3 		$1.24M Hold
138,646
– – ﹤0.01% 1831
2016
Q2 		$975K Buy
138,646
+30,600
+28% +$280K ﹤0.01% 1982
2016
Q1 		$887K Buy
108,046
+23,600
+28% +$232K ﹤0.01% 1971
2015
Q4 		$1.11M Buy
84,446
+17,946
+27% +$161K ﹤0.01% 1747
2015
Q3 		$243K Buy
66,500
+8,300
+14% +$40.6K ﹤0.01% 2451
2015
Q2 		$335K Buy
58,200
+10,200
+21% +$59K ﹤0.01% 2421
2015
Q1 		$280K Hold
48,000
– – ﹤0.01% 2411
2014
Q4 		$376K Buy
+48,000
New +$307K ﹤0.01% 2324

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Swiss National Bank's PACB Position: Q2 2025 in Review

Swiss National Bank sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 475,246 shares — an estimated $561K sold.

Swiss National Bank first reported a position in PACB in Q4 2014 and held it in 42 quarters. The position peaked at $14.1M in Q2 2021. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Swiss National Bank reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Swiss National Bank sold 475,246 Pacific Biosciences shares in Q2 2025, an estimated $561K.
  • Swiss National Bank first reported a position in Pacific Biosciences in Q4 2014 and held it in 42 quarters.
  • Swiss National Bank's Pacific Biosciences position peaked at $14.1M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Swiss National Bank's 13F filing for Q2 2025, filed 12 Aug 2025.